Subject(s)
Acute Kidney Injury/etiology , Calcinosis/etiology , Hypercalcemia/etiology , Multiple Myeloma/complications , Multiple Organ Failure/etiology , Acute Kidney Injury/therapy , Adult , Calcitonin/therapeutic use , Delayed Diagnosis , Emergencies , Encephalocele/etiology , Fatal Outcome , Hematoma, Subdural/etiology , Humans , Hypercalcemia/drug therapy , Immunoglobulin kappa-Chains/analysis , Male , Multiple Myeloma/diagnosis , Myeloma Proteins/analysis , Renal DialysisABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Immunosuppressive Agents/adverse effects , Lung Diseases, Interstitial/chemically induced , Sirolimus/adverse effects , Kidney TransplantationABSTRACT
BACKGROUND: The treatment of posttransplant secondary hyperparathyroidism (SHP) with vitamin D analogues is determined by their effectiveness to reverse hypercalcemia. Calcimimetics inhibit parathyroid hormone (PTH) secretion by modulating the calcium-sensing receptor in the parathyroid gland. Cinacalcet, a calcimimetic drug, has proven its effectiveness for the treatment of SHP among patients in phase V of chronic renal disease. PATIENTS AND METHODS: This retrospective analysis included 48 patients with SHP who were treated with cinacalcet. The initial dose of 30 mg/d could be increased to 180 mg, administering calcitriol also, depending on the serum calcium and PTH levels. The objectives were a PTH level between 75 and 125 pg/mL or a decrease >40%, and a serum calcium level below 10.5 mg/dL. RESULTS: The average PTH at baseline was 244 pg/mL, decreasing to 131 pg/mL at 1 year (P < .01). The average calcium at baseline was 10.1 mg/dL descending to 9.2 mg/dL at 1 year (P < .01). Among patients with hypercalcemia, the calcium decreased from 11 to 9.6 mg/dL at 1 year (P < .01). Seventy percent of patients without hypercalcemia reached the desired value of PTH, and 100% of those with hypercalcemia. Among patients with hypercalcemia, the desired calcium level was reached in 91% of cases. Ten patients developed hypocalcemia. In 3 cases we stopped the treatment with cinacalcet due to digestive intolerance. CONCLUSIONS: Treatment with cinacalcet controlled hyperparathyroidism and hypercalcemia among patients with posttransplant SHP. It was a safe drug, with a low incidence of side effects.
